Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;30(2):491-507.
doi: 10.1016/j.idc.2016.02.009.

Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches

Marisa Holubar  1 , Lina Meng  2 , Stan Deresinski  3
Affiliations
Review

Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches

Marisa Holubar et al. Infect Dis Clin North Am. 2016 Jun.

Abstract

This article reviews recent clinical evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Vancomycin remains the initial antibiotic of choice for the treatment of patients with MRSA bacteremia and endocarditis due to isolates with vancomycin minimum inhibitory concentration ≤2 μg/mL, whereas daptomycin is an effective alternative, and ceftaroline seems promising. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia and endocarditis.

Keywords: Bacteremia; Ceftaroline; Daptomycin; Endocarditis; MRSA; Methicillin; Staphylococcus aureus; Vancomycin.

PubMed Disclaimer

MeSH terms